Clinical effect observation of 125I seed implantation combined with endocrinal therapy for prostate cancer
10.3760/cma.j.issn.0254-5098.2012.05.013
- VernacularTitle:125I粒子植入联合内分泌治疗前列腺癌疗效观察
- Author:
Weijuan JIANG
;
Junjie WANG
;
Suqing TIAN
;
Yuliang JIANG
;
Lihong ZHU
;
Na MENG
;
Ruijie YANG
- Publication Type:Journal Article
- Keywords:
125I seed implantation;
Endocrinal therapy;
Prostate cancer
- From:
Chinese Journal of Radiological Medicine and Protection
2012;32(5):502-504
- CountryChina
- Language:Chinese
-
Abstract:
Objective To retrospectively study the efficacy and side-effect of 125I seed implantation combined with endocrinal therapy in stage T3N0M0 prostate cancer.Methods The study included 22 patients with clinical stage T3 N0 M0 prostate cancer who were treated with transperineal 125I seed implantation guided by transrectal ultrasound,real time TPS and endocrinal therapy.The minimum peripheral doses (MPD) were 140-160 Gy.The median number of seeds was 74(26-90).The activity of each seed was 1.55 × 107 (1.30 × 107-1.85 × 107) Bq.11 patients were treated with orchidectomy,and 11 patients were treated with androgen deprivation therapy.Results All 22 patients completed the seed implantation successfully.The 5-year biochemical progression-free survival was 70.6％,and 5-year overall survival was 81.8％.2 patients were found biochemical failure in 12 months after seed implantation,and another 1 patient failed in 90 months.Endocrinal therapy was followed thereafter.After the seed implantation,the urinary complications of grade 1 and 2 were 54.5％ and 9.1％ respectively,and the rectum side-effect of grade 1 and 2 were 22.7％ and 9.1％.1 patient suffered rectal complication of grade 4.Conclusions Good effect and tolerance are observed in prostate cancer patients of stage T3N0M0 receiving 125I seed implantation plus endocrinal therapy.The treatment can be considered for those who refuse to receive external beam radiotherapy.
